GeoVax to Present at the 36th Annual Roth Conference
12 mars 2024 09h00 HE
|
GeoVax, Inc.
ATLANTA, GA, March 12, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System
06 mars 2024 09h00 HE
|
GeoVax, Inc.
Manufacturing Process for Phase 3 and Commercial Production Being Developed for GeoVax MVA-Based Vaccines ATLANTA, GA, March 06, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc....
GeoVax Reports 2023 Year-End Financial Results and Provides Business Update
29 févr. 2024 16h00 HE
|
GeoVax, Inc.
Progress across the pipeline in multiple clinical trials, includingPhase 2 program of GEO-CM04S1, next-generation Covid-19 vaccine, andmulticenter Phase 1/2 study of Gedeptin®, targeting advanced...
GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024
22 févr. 2024 09h00 HE
|
GeoVax, Inc.
GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, GA, Feb. 22, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company...
GeoVax to Present at the 2024 BIO CEO & Investor Conference
19 févr. 2024 09h00 HE
|
GeoVax, Inc.
ATLANTA, GA, Feb. 19, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
GeoVax Announces Multiple Patent Issuances and Allowances
13 févr. 2024 09h00 HE
|
GeoVax, Inc.
Intellectual Property Assets Strengthened for Cancer Immunotherapy Programand for Marburg Virus and HIV Vaccines ATLANTA, GA, Feb. 13, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc....
GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster
06 févr. 2024 09h00 HE
|
GeoVax, Inc.
Results Demonstrate Potential Protective Immunity Against Multiple SARS-CoV-2 Variants ATLANTA, GA, Feb. 06, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a...
GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement
29 janv. 2024 09h00 HE
|
GeoVax, Inc.
ATLANTA, GA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology
08 janv. 2024 09h00 HE
|
GeoVax, Inc.
Strengthening GeoVax’s Team Advancing Gedeptin® Clinical Program ATLANTA, GA, Jan. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company...
GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients
04 janv. 2024 09h00 HE
|
GeoVax, Inc.
Therapy Demonstrated Safety, Stabilization/Shrinkage of Treated Tumors Expanded Development for Monotherapy and Combination Therapy Anticipated ATLANTA, GA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- via...